Description

Avelox (generic name: moxifloxacin hydrochloride; brand names include: Moxif / Vigamox) is a synthetic broad spectrum antibacterial agent of the fluoroquinolone class.

Avelox is highly active against many different bacteria, including those that are most likely to contribute to acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia.

Avelox has also been proven effective in the treatment of skin and skin structure infections and intra-abdominal infections caused by certain bacteria. Avelox rapidly travels to the site of infection, and provides fast clinical recovery.

Avelox has a well-characterized safety profile, which has been studied in over 14,000 patients in clinical trials and 92,000 patients in post marketing surveillance studies. Furthermore Avelox has been used to treat 109 million patients worldwide.